Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
32.90
-0.07 (-0.21%)
Jun 16, 2025, 4:00 PM - Market closed
HRMY Revenue
Harmony Biosciences Holdings had revenue of $184.73M in the quarter ending March 31, 2025, with 19.48% growth. This brings the company's revenue in the last twelve months to $744.85M, up 20.62% year-over-year. In the year 2024, Harmony Biosciences Holdings had annual revenue of $714.73M with 22.80% growth.
Revenue (ttm)
$744.85M
Revenue Growth
+20.62%
P/S Ratio
2.52
Revenue / Employee
$2,779,299
Employees
268
Market Cap
1.89B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HRMY News
- 5 days ago - Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire
- 11 days ago - Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation - Business Wire
- 12 days ago - Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 5 weeks ago - Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance - Business Wire
- 6 weeks ago - Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 - Business Wire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - Accesswire
- 2 months ago - Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - Business Wire